← Back to Cibo Flash
Earnings

Biostar Pharm-B (02563) announced interim results

  • RevenueRMB36.6M
  • Net profitRMB-26.6M
  • Profit attributable to ownersRMB-26.6M
  • Revenue YoY+147.8%
  • Net profit YoY+50.8%
  • Depreciation & amortisationHK$10.6M
  • Capital expenditureHK$-5.4M
  • Interest-bearing debtHK$927,401

Source Biostar Pharm-B

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect